ORIGINAL PAPER
A decade of neonatal polycythaemia – has anything changed in this field?
More details
Hide details
1
Department of Neonatology, Clinic for Children’s Diseases, University Clinical Hospital Mostar, School of Medicine University of Mostar, Mostar, Bosnia and Herzegovina
These authors had equal contribution to this work
Submission date: 2023-11-11
Final revision date: 2024-01-02
Acceptance date: 2024-01-15
Publication date: 2024-05-27
Corresponding author
Marjana Jerković Raguž
Marjana Jerković Raguž, PhD, Department of Neonatology, Clinic for Children Disease, School of Medicine University Mostar, Mostar, Bosnia and Herzegovina
Pediatr Pol 2024;99(2):99-104
KEYWORDS
TOPICS
ABSTRACT
Introduction:
This study aims to determine the prevalence, clinical features, and methods of treating polycythaemia (PC) and hyperviscosity (HVS) syndrome in newborns over a 10-year period (2012–2022). Furthermore, it aims to determine whether there have been changes in the incidence of PC in the region encompassed by the study.
Material and methods:
This retrospective study sample included all the newborns with a diagnosis upon admittance and discharge of PC and HVS syndrome.
Results:
Incidence of PC and HVS syndrome was 0.8% (153/18.407) of the total number of babies born and 2.8% (153/5.483) of the treated newborn. Polycythaemia was more common in newborn males, in newborn weighing more than 2500 grams, with normal vitality scores, born at full term, and with other pathological conditions. The most common pathological condition in the newborn with PC was jaundice, and the most common symptoms were plethoric and dry skin, rash, and hypotonia. Furthermore, mothers with and without pathological conditions, who gave birth naturally, were equally represented.
Conclusions:
This 10-year study concludes that the prevalence of PC was constant over the years. Furthermore, mothers with and without pathological conditions, who gave birth naturally, were equally represented. The newborns were more frequently male, full-term babies, with good vitality scores and birth weights. Also, all the above leads to the conclusion that the newborns had passive PC that was not caused by a medical indication at birth, which led to the spectrum of various symptoms and pathological conditions that accompany PC. On the basis of the above results, it can be concluded that PC is most often passive in our region, which is why PC must be taken into consideration in the daily care of newborns despite the controversial opinions on the above-mentioned pathology.
REFERENCES (15)
1.
Gordon EA. Polycythemia and hyperviscosity of the newborn. J Perinat Neonatal Nurs 2003; 17: 209-219.
2.
Jeevasankar M, Agarwal R, Chawla D, Paul VK, Deorari AK. Polycythemia in the newborn. Indian J Pediatr 2008; 75: 68-72.
3.
Rincon D, Foguet A, Rojas M, et al. Time of cord clamping and neonatal complications, a prospective study. An Pediatr (Barc) 2014; 81: 142-148.
4.
Verbeek L, Slaghekke F, Sueters M, et al. Hematological disorders at birth in complicated monochorionic twins. Expert Rev Hematol 2017; 10: 525-532.
5.
Mercer JS, Erickson-Owens DA, Collins J, Barcelos MO, Parker AB, Padbury JF. Effects of delayed cord clamping on residual placental blood volume, hemoglobin and bilirubin levels in term infants: a randomized controlled trial. J Perinatol 2017; 37: 260-264. .
6.
Bashir BA, Othman SA. Neonatal polycythaemia. Sudan J Paediatr 2019; 19: 81-83.
7.
Monzani A, Remorgida V, Rabbone I. High rates of neonatal polycythemia and hyperbilirubinemia during the first phase of COVID-19 pandemic in Italy: a single-center experience. Ital J Pediatr 2022; 48: 100.
8.
Sarkar S, Rosenkrantz TS. Neonatal polycythemia and hyperviscosity. Semin Fetal Neonatal Med 2008; 13: 248-255.
9.
Schimmel MS, Bromiker R, Soll RF. Neonatal polycythemia: is partial exchange transfusion justified? Clin Perinatol 2004; 31: 545-553. .
10.
Rkin SH, Nathan DG, Ginsburg D, Look AT, Brugnara C, Platt OS. The neonatal erythrocyte and its disorders. In: Orkin SH, Nathan DG, Ginsburg D, Look AT (eds.). Nathan and Oski’s hematology of infancy and childhood. 7th ed. Vol. 1. Elsevier, Philadelphia, PA 2009, 36-66.
11.
Alsafadi TR, Hashmi SM, Youssef HA, Suliman AK, Abbas HM, Albaloushi MH. Polycythemia in neonatal intensive care unit, risk factors, symptoms, pattern, and management controversy. J Clin Neonatol 2014; 3: 93-98.
12.
Wiswell TE, Cornish JD, Northam RS. Neonatal polycythemia: frequency of clinical manifestations and other associated findings. Pediatrics 1986; 78: 26-30.
13.
Rosenkrantz TS. Polycythemia and hyperviscosity in the newborn. Semin ThrombHemost 2003; 29: 515-527.
14.
Hopfeld-Fogel A, Kasirer Y, Mimouni FB, Hammerman C, Bin-Nun A. Neonatal polycythemia and hypoglycemia in newborns: are they related? Am J Perinatol 2021; 38: 930-934.
15.
Ozek E, Soll R, Schimmel MS. Partial exchange transfusion to prevent neurodevelopmental disability in infants with polycythemia. Cochrane Database Syst Rev 2010; 20: CD005089.